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Bone marrow and peripheral blood samples from 362 patients with acute lymphoblastic leukaemia (ALL) proliferating cell and 90
patients with acute myeloid leukaemia (AML) were analysed for S-phase fractions, Ki67 antigen, and proliferating cell nuclear antigen
expression. The S-phase fractions were correlated with in vitro drug resistance to 15 different anticancer agents. Leukaemia cells
isolated from bone marrow had higher S-phase fractions than leukaemia cells isolated from peripheral blood (in initial ALL, median
values resp. 6.9 and 2.7%, in initial AML resp. 5.3 and 1.3%; both Po0.01). Relapse ALL samples derived from bone marrow showed
increased S-phase fractions (median 9.9%) compared with initial ALL samples (median 6.9%; Po0.01). ALL samples obtained at initial
diagnosis showed higher S-phase fractions (median 6.9%) and higher Ki67 expression (median 30%) than initial AML samples (median
resp. 5.3 and 14%; both Po0.05). The S-phase fractions were not related to white blood cell count, age, or gender. Within initial ALL,
the S-phase fraction correlated significantly but modestly strong (r¼0.3–0.5; Po0.05) with sensitivity to antimetabolites (cytarabine,
mercaptopurine, thioguanine), L-asparaginase, teniposide, and vincristine. Similar results were found within subgroups of initial ALL
(nonhyperdiploid and common/precursor-B-lineage ALL). In relapsed ALL and AML such correlations were not found. In conclusion,
cell proliferation differs between leukaemia subgroups and increased proliferation is associated with increased in vitro sensitivity to
several anticancer agents in initial ALL.
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The prognosis of childhood acute leukaemia has improved during
the past decades. This has been accomplished by the introduction
of refined schedules of combination chemotherapy (Reiter et al,
1994; Pui and Evans, 1998; Stevens et al, 1998; Creutzig et al, 2001).
As a consequence of the improved prognosis and risk-adapted
treatment, the prognostic significance of a number of parameters
at presentation has decreased. At present, the most important
prognostic features are age at presentation, white blood cell count,
cell morphology, immunophenotype, and genotype (DNA ploidy
and certain chromosomal abnormalities) (Creutzig et al, 1990;
Kersey, 1997; Pui and Evans, 1999). More recently, in vitro drug
resistance (Klumper et al, 1995b; Hongo et al, 1997; Kaspers et al,
1997, 1998; Asselin et al, 1999) and the presence of minimal
residual disease (Van Dongen et al, 1998; Eckert et al, 2001; Nyvold
et al, 2002) in the course of treatment have shown to be strong
independent prognostic factors in childhood acute lymphoblastic
leukaemia (ALL).
Contradictory findings have been reported concerning the
prognostic value of the S-phase fractions of leukaemia cells. In
childhood acute leukaemia, the S-phase fraction has been found to
correlate with clinical (prognosis and age) and cell biological
features (immunophenotype and genotype) at presentation (Dow
et al, 1982; Look et al, 1982; Smets et al, 1983, 1995; Duque et al,
1993; Vidriales et al, 1995; Kamikubo et al, 2000; Braess et al,
2001). A review of the literature stated, however, that the S-phase
fractions were not prognostic for treatment response or response
duration in acute leukaemia in general (Duque et al, 1993).
Nevertheless, others reported that bone marrow S-phase fractions
of 46% were shown to be strongly predictive for poor outcome in
childhood ALL patients (Dow et al, 1982; Smets et al, 1995). In
agreement with these findings, in 204 acute myeloblastic leukaemia
(AML) patients, a high number of cells in S phase related to shorter
survival (Vidriales et al, 1995) and a low proportion of G0-phase
cells during induction chemotherapy correlated with subsequent
remission in AML (Kamikubo et al, 2000). In contrast, however, in
a recent study with 187 AML samples that were cytogenetically
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sclassified into prognostic subgroups, a high proliferative activity
was associated with a higher complete remission rate in both the
normal (n¼99) and unfavourable groups (n¼29) (Braess et al,
2001).
It has been demonstrated by others that stimulation of cell
proliferation of leukaemia cells by preincubation with growth
factors could enhance in vitro sensitivity to cytarabine (Butturini
et al, 1990; Bai et al, 1999). This indicates that pretreatment with
growth factors as chemosensitising approach may be useful for
patients with childhood acute leukaemia. In the present study, it
was investigated if cell proliferation of acute childhood leukaemia
was related to in vitro drug resistance. This was determined by
analysing the correlation between the S-phase fractions and the in
vitro resistance to 15 different anticancer agents assessed with the
methyl-thiazol–tetrazolium (MTT) assay.
MATERIALS AND METHODS
Peripheral blood and bone marrow samples
The local ethical committee has given its permission to perform
this study. Bone marrow and peripheral blood samples were
collected with informed consent from a total of 452 children with
acute leukaemia. From these patients, 362 were diagnosed as ALL
and 90 as AML. From the ALL patients, 213 samples were taken at
initial diagnosis and 149 at relapsed disease. For the AML samples,
68 were obtained from patients at initial diagnosis and the
remaining 22 samples from relapsed patients. In total, 282 bone
marrow and 170 peripheral blood samples were included. This
cohort of samples has been used for several studies over the past
years, but no data have been reported that were focused on drug
resistance in relation to cell proliferation. Six different groups
participated in the study: the Dutch Childhood Leukaemia Study
Group (DCLSG, Den Haag, The Netherlands); the Sophia
Children’s Hospital, Rotterdam, The Netherlands; the COALL
Study Group (Hamburg, Germany); the ALL-BFM Study Group
(Berlin, Germany); the AML-BFM Study Group (Mu ¨nster, Ger-
many); the Rigshospitalet, Copenhagen, Denmark. Immunophe-
notyping and DNA index flow cytometry were performed following
standard procedures at the reference laboratories of the participat-
ing groups. Hyperdiploid samples were defined as having a DNA
index between 1.16 and 1.35 (Pui et al, 1990; Smets et al, 1995).
B-lineage immunophenotype was defined as HLA-DR
+/terminal
deoxynucleotidyl transferase (TdT)
+/CD19
+ ALL and further
differentiated as follows: pro-B-ALL (CD10
 /cytoplasmic m chain
(cm)
 /surface immunoglobulin (sIg)
 ), common (c)-ALL (CD10
+/
cm
 /sIg
 ) and precursor-B (pre-B)-ALL (CD10
+ or CD10
 /cm
+/
sIg
 ). T-lineage (T)-ALL was defined by TdT
+/cytoplasmic
CD3
+/CD7
+. Patient characteristics (gender, age, white blood cell
count at diagnosis) were collected by study centers.
Isolation of leukaemia cells
Within 24h (and in a few cases within 48h) after sampling,
mononuclear cells were separated by density gradient centrifuga-
tion at 480g for 15min (Lymphoprep, 1.077gml
 1, Nycomed
Pharma, Oslo, Norway). After washing, the cells were resuspended
into culture medium consisting of RPMI 1640 (Dutch modification
without L-glutamine; Gibco BRL, Breda, The Netherlands),
containing 20% fetal calf serum (FCS; Integro, Zaandam, The
Netherlands), 2mM L-glutamine (ICN Biochemicals, Costa Mesa
CA, USA), ITS media supplement (5mgml
 1 insulin, 5mgml
 1
transferrin, 5ngml
 1 sodium selenite) (Sigma, St Louis MO, USA),
80IUml
 1 penicillin (Gibco BRL Breda, The Netherlands)
80mgml
 1 streptomycin (Gibco BRL), 0.1mgml
 1 fungizone
(ICN Biomedicals), and 0.2mgml
 1 gentamycin (Flow Labora-
tories, Irvine, Scotland). Contaminating lymphocytes were re-
moved using immunomagnetic beads as described previously
(Kaspers et al, 1994). This procedure was carried out at room
temperature instead of at 371C in order to avoid phagocytosis of
the beads by the myeloid leukaemia cells. Isolated cells were
collected in the culture medium. Only samples that contained more
than 80% leukaemic cells, as determined by cytospin preparations
stained with May–Gru ¨nwald–Giemsa (Merck, Darmstadt, Ger-
many) were included. Not from all samples all parameters could be
tested because of limited number of cells and/or failing test(s).
Methods used for determination of cell proliferation
Only samples that were taken within 24h after sampling were used
for determination of cell proliferation.
Analysis of S-phase fractions by flow cytometry
Propidium iodide (PI) is a substance that intercalates into double-
helical regions of both DNA and RNA molecules. For detection of
the DNA content only, isolated leukaemia cells (fixed with 70%
ethanol, stored at 41C) were pretreated with trypsin (T0134, Sigma)
for 5min at room temperature. Subsequently, cells were incubated
with ribonuclease A (R4875, Sigma) and trypsin inhibitor (T9253,
Sigma) for 10min at room temperature according to the protocol
of Vindelov et al (1983a). Fixed cells were stained with PI (Sigma,
St Louis MO, USA) for 15min on ice. Trout red blood cells, which
have a DNA content of 80% of the human diploid value, were used
as internal reference (Vindelov et al, 1983b). The intracellular DNA
content was determined by the mean fluorescence intensity of
gated leukaemia cells and was expressed as the percentage of all
cells in the S phase, which was calculated with the Cell Fit software
program for DNA cell cycle analysis (Becton and Dickinson,
Mountain View, CA). Since only samples that contained more than
80% leukaemic cells were included, it was assumed that aneuploidy
of the leukaemia cells did not interfere with the calculation of the
S-phase fraction.
Flow cytometric detection of proliferation-associated
antigens
Ki67 is a nuclear antigen expressed in all phases of the cell cycle,
except in the G0- and early G1-phase. Expression of Ki67 increases
with cell cycle progression, and has its maximum expression in late
S- and G2-phases. Proliferation cell nuclear antigen (PCNA) is the
polymerase delta accessory molecule, which plays a role in
nucleotide excision repair, and has its maximum concentration
at the S- and late G1-phase. PCNA is a marker of G1-, S-, G2- and
M-phases of the cell cycle. However, because of the relatively long
half-life time, PCNA may also be detected in cells that are in the
G0-phase.
Isolated leukaemia cells were fixed for 15min by gently
dropping ice-cold methanol on the cell pellet at  201C. Fixed
leukaemia cells were washed and incubated for 45min at room
temperature with monoclonal antibodies against Ki67 antigen
(1:10) (DAKO, Glostrup, Denmark), PCNA (1:100) (DAKO), or
control IgG1 (1:400) (ITK Diagnostics, Uithoorn, The Nether-
lands) diluted in phosphate-buffered saline (PBS) containing 1%
bovine serum albumine (BSA). Subsequently, cells were washed
and incubated for 30min at room temperature with FITC-
conjugated rabbit-anti-mouse F(ab0)2 fragments (1:50; DAKO)
diluted in PBS containing 1% BSA and 2% pooled human serum.
After washing, green fluorescence intensity was detected by flow
cytometry through a 530/30nm bandpass filter set (FACScan;
Becton and Dickinson, Erembodegem, Belgium). The expression of
the proliferation-associated antigens was determined by the mean
fluorescence intensity of gated leukaemia cells and was expressed
as the percentage of positively stained cells in relation to the total
amount of cells. Positively stained cells were defined as cells that
showed higher fluorescence intensity as compared to the highest
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sfluorescence intensity of cells that were incubated with control
IgG1 (set as marker).
In vitro drug resistance assay
The MTT assay was performed as described previously (Kaspers
et al, 1991). In short, isolated leukaemia cells were exposed to six
different concentrations of the selected drugs. After 4 days of
incubation in 5% CO2 humidified air at 371C, 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazoliumbromide (Sigma, St Louis MO,
USA) was added and cells were incubated for another 6h.
Subsequently, formazan crystals formed were dissolved in acidified
isopropanol. The optical density, which appeared linearly related
to the number of viable cells (Kaspers et al, 1991), was measured at
562nm (Bio-Kinetics Reader, Bio-Tek Instruments, Winooski VT,
USA). Samples with less than 70% of leukaemia cells in control
wells after 4 days of culture and/or an optical density below 0.050
arbitrary units (adjusted for blank values) were considered not
valuable and were excluded from the study. The LC50 values, that
is, the drug concentration that killed 50% of the cells, were
calculated. The in vitro drug resistance was determined for the
following 15 drugs: 0.008–8.0mgml
 1 aclarubicin (Lundbeck A/S,
Copenhagen, Denmark), 0.002–2.5mgml
 1 cytarabine (Pharmacia
& Upjohn, Woerden, The Netherlands), 0.002–2mgml
 1 dauno-
rubicin (Rho ˆne Poulenc Rorer, Amstelveen, The Netherlands),
0.002–6mgml
 1 dexamethasone disodiumphosphate (Bufa
Pharmaceutical Products, Uitgeest, The Netherlands), 0.008–
8mgml
 1 doxorubicin (Pharmacia & Upjohn, Woerdon, The
Netherlands), 0.05–50mgml
 1 etoposide (Bristol-Myers Squib,
Woerden, The Netherlands), 0.1–100mgml
 1 4-hydroperoxy
ifosfamide, which is the active metabolite of ifosfamide (Asta-
Medica, Diemen, The Netherlands), 0.002–2mgml
 1 idarubicin
(Pharmacia & Upjohn), 0.003–10IU L-asparaginase (Christiaens,
Breda, The Netherlands), 15.6–500mgml
 1 mercaptopurine
(Glaxo Wellcome, Zeist, The Netherlands), 0.001–1mgml
 1
mitoxantrone (AHP Pharma Weyth Lederle, Hoofddorp, The
Netherlands), 0.008–2000mgml
 1 prednisolone disodiumpho-
sphate (Bufa Pharmaceutical Products), 0.003–8mgml
 1 tenipo-
side (Bristol-Myers Squib Uitegeest, The Netherlands), 1.56–
50mgml
 1 thioguanine (Glaxo Wellcome, Zeist, The Netherlands),
and 0.05–50mgml
 1 vincristine (Eli Lilly, Houten, The Nether-
lands).
Statistical data analysis
Differences in the distributions of variables between two groups
were analysed by the Mann–Whitney U-test. In order to identify a
relation between two variables within one group, the Spearman
rank correlation coefficients were calculated. If less than nine
samples were available, however, this was considered as too small a
number for meaningful analysis. All analyses were two-tailed and
differences were considered statistically significant when Pp0.05.
The samples taken at initial diagnoses and the samples taken at
relapse are largely unmatched, that is, from different individuals.
RESULTS
Cell proliferation
Peripheral blood vs bone marrow samples In both ALL and AML
samples taken at initial diagnosis, the S-phase fraction was higher
in bone marrow than in peripheral blood samples (in initial ALL,
median values resp. 6.9 and 2.7%; in initial AML resp. 5.3 and
1.3%; both Po0.01) (Figure 1). Similarly, in ALL samples, but not
in AML samples, taken at relapse more leukaemia cells in S-phase
were detected in bone marrow as compared with peripheral blood
samples (in relapsed ALL, median values resp. 9.9 and 4.9%;
Po0.01) (Figure 1). However, no significant differences in Ki67 or
PCNA expression were found between bone marrow and
peripheral blood samples. In general, the expression of Ki67
antigen varied greatly from patient to patient, whereas the
expression of PCNA was generally high in all patients (Figure 2).
Since the S-phase fraction differed between the bone marrow and
peripheral blood samples, the cell proliferation data were analysed
separately for both types of samples. It was decided to further limit
the analysis of the cell proliferation data to bone marrow as the site
of origin of leukaemia and the main location of minimal residual
disease and initial site of relapses. Data on cell proliferation are
illustrated in Figures 1 and 2. Taking all bone marrow samples
together irrespective of disease, the S-phase correlated both with
Ki67 (n¼155, r¼0.32, Po0.01) and PCNA expression (n¼152,
r¼0.24, Po0.05), and the Ki67 expression correlated with the
PCNA expression (n¼176, r¼0.352, Po0.01).
Initial vs relapsed acute leukaemia
In ALL bone marrow samples from relapsed patients an increased
number of cells in S phase was detected when compared with ALL
bone marrow samples from initial patients (median values, resp.
9.9 and 6.9%; Po0.01). However, no significant differences in Ki67
and PCNA expression were detected. No differences in cell
proliferation parameters were found between initial and relapsed
AML. Within the initial ALL samples, the S-phase fractions
correlated with both Ki67 (n¼62, r¼0.37; Po0.01) and PCNA
expression (n¼61, r¼0.30; Po0.05). In addition, Ki67 expression
was related to PCNA expression (n¼70, r¼0.46; Po0.01). In the
relapse ALL samples, Ki67 expression was related to the S-phase
fraction (n¼44, r¼0.34, Po0.05). Within all AML samples, the
S-phase fraction was related to Ki67 expression (n¼34, r¼0.38,
Po0.05). However, there was discrepancy between the S-phase
fraction and the expression of Ki67 and PCNA in both the initial
AML and relapse AML samples, probably because of the low
number of samples tested (maximum number of samples tested
resp. n¼28 and 9). Data are illustrated in Figures 1 and 2.
Acute lymphoblastic vs myeloblastic leukaemia
A higher number of cells in S-phase were detected in initial ALL
bone marrow samples compared to initial AML bone marrow
samples (median value of 6.9% in ALL and 5.3% in AML; Po0.05).
In addition, a higher expression of Ki67 was found in initial ALL
samples when compared with initial AML samples (median value
of 30% in ALL and 14% in AML; Po0.05). No significant
difference between ALL and AML samples was found in the PCNA
expression. Comparing the relapse ALL samples with the relapse
AML samples, no significant differences were found in the various
cell proliferation features. Data are illustrated in Figures 1 and 2.
In vitro drug resistance
In correspondence with our previous data, no differences were
found in resistance to any of the drugs between bone marrow and
peripheral blood samples (Kaspers et al, 1991; Klumper et al,
1995a). For this reason, the drug resistance data of bone marrow
and peripheral blood samples were analysed all together. Drug
resistance data obtained in the present study are largely in
agreement with previously published findings of our group
(Klumper et al, 1995a,b; Zwaan et al, 2000). Summarising,
leukaemia cells isolated from ALL patients were significantly more
sensitive than those derived from AML patients to 12 out of the 15
drugs: prednisolone, dexamethasone, L-asparaginase, vincristine,
daunorubicin, doxorubicin, idarubicin, aclarubicin, mitoxantrone,
etoposide, teniposide, and 4-hydroperoxy ifosfamide. The ALL
samples taken at initial diagnosis were more sensitive compared
with relapse ALL samples to eight out of the 15 drugs:
prednisolone, dexamethasone, L-asparaginase, vincristine, dauno-
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srubicin, doxorubicin, idarubicin, and thioguanine. For the AML
samples, the in vitro drug resistance did not differ significantly
between initial and relapse samples, but the numbers were small in
the latter group.
Correlation between S-phase fractions and in vitro drug
resistance
The S-phase fractions, but not the expression of Ki67 or PCNA,
showed differences between bone marrow vs peripheral blood
samples as well as between initial vs relapsed ALL. For this reason,
it was decided to restrict the correlation data of in vitro drug
resistance to S-phase fractions only. However, essentially similar
results were found for the other proliferation parameters. All
significant correlations that were found between S-phase fractions
and drug resistance were inverse, that is, higher S-phase fractions
were related to lower LC50 values or a more drug-sensitive
phenotype. In ALL samples taken at initial diagnosis increased
S-phase fractions correlated with sensitivity to cytarabine,
L-asparaginase, mercaptopurine, teniposide, thioguanine, and
vincristine (Table 1). For the ALL samples taken at relapsed
disease, the S-phase fractions did not correlate with sensitivity to
any of the tested drugs (Table 1). Within AML samples taken at
initial diagnosis, a correlation was found between the S-phase
fraction and sensitivity to dexamethasone (Table 1). Although it
has to be mentioned that most AML samples tested were extremely
resistant for dexamethasone and the number of tested AML
samples for this particular drug was small (n¼12). No relations
were found between the S-phase fractions and in vitro drug
resistance in AML samples taken at relapsed disease, although the
number of samples in this group was rather small (Table 1).
Correlation between S-phase fractions and in vitro drug
resistance within subgroups of initial ALL
Within the ALL bone marrow samples taken at initial diagnosis,
the S phase was not related to white blood cell count, age, or
gender. Within the initial ALL samples, the hyperdiploid samples
(n¼31), defined as having a DNA index between 1.16 and 1.35
(Pui et al, 1990; Smets et al, 1995), had a significantly higher S-
phase fraction (median value 7.9%) compared to nonhyperdiploid
samples (n¼83; median S-phase fraction of 6.3%; P¼0.04).
Within this hyperdiploid subgroup no correlations were found
between S phase and in vitro resistance to any of the tested drugs,
probably because of the small numbers of samples that were tested
for both parameters (maximum of n¼18). Within the nonhyper-
diploid subgroup, a higher S phase was significantly related to
increased sensitivity to cytarabine (r¼ 0.35; P¼0.02), L-
asparaginase (r¼ 0.36; P¼0.02), mercaptopurine (r¼ 0.44;
P¼0.003), mitoxantrone (r¼ 0.31; P¼0.05), teniposide
(r¼ 0.39; P¼0.01), and thioguanine (r¼ 0.39; P¼0.01)
(maximum of n¼45 with both parameters available). Within
the initial ALL samples, the two major immunophenotypic
subgroups, that is, common/precursor-B-lineage (c/pre-B-)ALL,
and T-lineage (T-)ALL differed significantly (P¼0.02) in S-phase
fractions (S-phase fraction of 6.7% (n¼83) and 11.3%, respec-
tively (n¼11). Within the c/pre-B-ALL, increased sensitivity to
both L-asparaginase (r¼ 0.32; P¼0.02) and mercaptopurine
(r¼ 0.39; P¼0.01) was significantly related to a higher S-phase
fraction (maximum of n¼51 with both parameters available).
Within the T-ALL subgroup, the number of samples analysed for
both parameters was too small for analysis (n¼5).
DISCUSSION
In the present study, cell proliferation of different subgroups
of childhood acute leukaemia was defined and correlated
with in vitro drug resistance. Bone marrow samples had generally
a higher S-phase fraction than blood samples, which is in
correspondence with previous findings of Dow et al (1982).
The high proliferative activity of bone marrow leukaemia cells
might be caused by stimulation with growth factor-producing
stromal cells that are present in the patient’s bone marrow. This is
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Figure 1 Comparison of S-phase fractions of peripheral blood (PB) vs bone marrow (BM) samples. Represented are the percentages of cells in S phase
for the ALL and AML samples derived from BM or PB. The median value is shown as horizontal bar. Both the initial and relapse ALL samples as well as the
initial AML samples derived from BM had a significantly higher S-phase fraction than those derived from PB (*,
+,
#; Po0.01). The BM-derived ALL samples
taken at initial diagnosis differed significantly from those taken at relapsed disease in the S-phase fraction (**; Po0.01). In addition, the BM-derived ALL
samples taken at initial diagnosis differed significantly from the initial AML samples (
++; Po0.05). iALL and iAML, samples taken at initial diagnosis; rALL and
rAML, samples taken at relapsed disease.
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sstrengthened by the fact that at the end of the in vitro drug assay,
after 4 days of culture without growth factors, no significant
differences were detected anymore in the S-phase fractions
between the leukaemia cells derived from bone marrow and blood
(data not shown).
The S-phase fraction (but not Ki67 and PCNA expression) of
relapse ALL samples was significantly higher than that of initial
ALL samples. In addition, both the S-phase fraction and Ki67
expression (but not PCNA expression) were significantly higher in
childhood ALL than in childhood AML samples, which is in
agreement with other findings (Ito et al, 1992). The expression of
Ki67 antigen differed greatly from patient to patient whereas the
expression of PCNA was generally high in all acute leukaemia
patients, which is in accordance with previous reports (Ito et al,
1992; Tsurusawa et al, 1992). The high percentage of cells that were
positive for PCNA in all leukaemia subgroups can be explained by
the long half-life time of this antigen. In conclusion, PCNA and
Ki67 appeared to be less attractive as proliferation markers than
the S-phase fraction, since these markers were not able to
differentiate the various subgroups of childhood acute leukaemia.
In vitro drug resistance, assessed with the MTT assay, is
significantly related to the clinical response to chemotherapy in
childhood ALL (Klumper et al, 1995b; Hongo et al, 1997; Kaspers
et al, 1997, 1998; Asselin et al, 1999). In addition, in childhood
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Figure 2 (A) Represented are the percentages of Ki67-positive cells for the different childhood acute leukaemia subgroups. The median value is shown as
horizontal bar. The ALL samples taken at initial diagnosis differed significantly from the AML samples taken at initial diagnosis in Ki67 expression (*; Po0.05).
iALL and iAML, samples taken at initial diagnosis; rALL and rAML, samples taken at relapsed disease. (B) Represented are the percentages of PCNA-positive
cells for the different childhood acute leukaemia subgroups. The median value is shown as horizontal bar. No significant differences in PCNA expression in
the different subgroups were observed. iALL and iAML, samples taken at initial diagnosis; rALL and rAML, samples taken at relapsed disease.
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sAML clinical outcome and in vitro drug resistance showed to
correlate as well (Klumper et al, 1995a). In the present study an
increased in vitro sensitivity to antimetabolites (cytarabine,
mercaptopurine, thioguanine), L-asparaginase, vincristine, and
teniposide was related to a higher S-phase fraction of leukaemia
cells isolated from initial childhood ALL patients. In addition,
the other proliferative markers (Ki67 and PCNA) were related
to the antimetabolites, vincristine, teniposide as well as for
the anthracyclins (data not shown). It is understandable that
the antimetabolites were related to cell proliferation since these
drugs inhibit DNA and RNA synthesis, and are therefore
especially effective for cells in S-phase. A relation between
high S-phase fraction of leukaemia cells and an increased
sensitivity to vincristine or L-asparaginase has not been described
before in the literature. Additionally, we found a relation
between an increased sensitivity to the epipodophyllotoxin,
teniposide, and a higher S-phase fraction. Epipodophyllotoxins
are inhibitors of topoisomerase-II-alpha that are expressed in
a cell cycle-dependent manner (Kellner et al, 2000). We did not
find, however, a relation between the S-phase fraction and
sensitivity to anthracyclines that are also known to inhibit
topoisomerase-II, although anthracyclins share other action
mechanisms also.
Within the initial ALL samples, a correlation between a higher
S-phase fraction and an increased sensitivity to various drugs was
also observed in the nonhyperdiploid subgroup (cytarabine, L-
asparaginase, mercaptopurine, mitoxantrone, teniposide, and
thioguanine) as well as in the c/pre-B ALL subgroup (L-
asparaginase, mercaptopurine). Moreover, within the initial ALL
samples, the S-phase fraction was not related to white blood cell
count, age, or gender. These findings further supports the idea that
there is a direct relation between cell proliferation and drug
sensitivity in childhood ALL at initial diagnosis and that the
observed relation not merely reflects a difference in both cell
proliferation and in vitro drug sensitivity in the various ALL
subgroups. Both in relapse ALL samples and in AML samples, no
such relation was found between S-phase fraction and in vitro drug
resistance as in the initial ALL samples.
Relapse ALL samples had an increased S-phase fraction and they
were more resistant to various drugs than intial ALL samples.
Apparently, not only the proliferative status of leukaemia cells
accounts for its primary response to a particular drug. Especially
for leukaemia cells from relapsed disease, drug-resistant clones
may have emerged and for these cells intrinsic cellular resistance
probably plays a more important role in the response to drugs than
the proliferative status.
An increased proliferative activity may increase the sensitivity
to particular drugs, therefore pretreatment with growth factors
prior to treatment with these proliferation-dependent drugs
may increase the response rate in childhood acute leukaemia.
Several studies have indeed demonstrated that the in vitro
sensitivity to cytarabine of AML cells could be enhanced by
preincubation with granulocyte colony-stimulating factor (G-CSF)
and/or with granulocyte–macrophage colony-stimulating factor
(GM-CSF) (Butturini et al, 1990; Bai et al, 1999). Clinically,
pretreatment with G-CSF (as in the FLAG regimen, which is a
combination therapy of fludarabine, cytarabine, and G-CSF),
seems to be effective and well tolerated in the treatment of poor-
risk AML patients (Montillo et al, 1998; Jackson et al, 2001). The
efficacy of this therapy, however, has not yet been determined in a
controlled, randomised clinical study. In the present study,
especially the S-phase fractions of untreated childhood ALL
samples appeared to correlate with the in vitro sensitivity to a
number of anticancer agents. In childhood ALL patients pretreat-
ment with growth factors has not been adequately investigated as a
chemosensitising approach, but the present data do suggest that
this approach may be useful.
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